Orange, Calif.-based UCI Health has appointed Melanie Joe, PharmD, vice president and system chief pharmacy officer. Dr. Joe is responsible for developing the strategic vision for UCI Health Pharmaceutical Services, according to a LinkedIn post from the UC Irvine School…

A September white paper from Pioneer Institute and CancerCare compared nearly 4,000 hospitals using CMS cost report data linked to HRSA’s 340B covered-entity records to examine differences in patient assistance measures between 340B and non-340B hospitals. Here are six things…

The Trump administration is developing an initiative aimed at moving production of 86 essential medicines to the U.S. within 18 months, according to a Sept. 25 Bloomberg report. Under the initiative, the Office of Management and Budget would solicit proposals…

Inventia Healthcare Limited has recalled 13,567 bottles of chlorthalidone tablets after the product failed dissolution specifications. The voluntary recall covers Chlorthalidone Tablets, USP, 25 milligram, packaged in 100-tablet bottles and distributed nationwide, according to an FDA enforcement report. The affected…

New customs requirements taking effect Oct. 22 could disrupt access for millions of Americans who buy prescription drugs from Canadian and other foreign mail-order pharmacies, according to a Sept. 24 report from The Wall Street Journal. Here are three things…

The American Hospital Association is urging Congress to permanently bar rebate models in the 340B program.  AHA issued the request in Sept. 23 comments on the SECURE 340B Act. Lawmakers introduced the bipartisan bill in July. The legislation combines protections…

Eli Lilly received FDA approval Sept. 24 for Onswik, a once-weekly basal insulin injection for adults with Type 2 diabetes. The FDA approved Onswik for use alongside diet and exercise to improve glycemic control. The drug delivers steady basal insulin…

A Sept. 24 Peterson-KFF Health System Tracker analysis compared TrumpRx prices for 32 brand-name drugs without generic or biosimilar competition with publicly listed prices in 11 peer OECD countries. Here are six findings to know:

More than 1 in 5 older U.S. adults were potentially at risk of a major drug-drug interaction from 2021 to 2023, according to a study published Sept. 24 in JAMA. Researchers analyzed nationally representative data from community-dwelling adults ages 62…

The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted Sept. 23 in favor of approving Grail’s Galleri multi-cancer early-detection blood test. The vote marks the first time a test of this kind has reached this…